Department of Translational Medicine, Università del Piemonte Orientale (UPO), 28100 Novara, Italy.
Department of Internal Medicine and COVID-19 Unit, Azienda Ospedaliero-Universitaria (AOU) "Maggiore della Carità", 28100 Novara, Italy.
Nutrients. 2023 Mar 4;15(5):1285. doi: 10.3390/nu15051285.
As lactoferrin is a nutritional supplement with proven antiviral and immunomodulatory abilities, it may be used to improve the clinical course of COVID-19. The clinical efficacy and safety of bovine lactoferrin were evaluated in the LAC randomized double-blind placebo-controlled trial. A total of 218 hospitalized adult patients with moderate-to-severe COVID-19 were randomized to receive 800 mg/die oral bovine lactoferrin (n = 113) or placebo (n = 105), both given in combination with standard COVID-19 therapy. No differences in lactoferrin vs. placebo were observed in the primary outcomes: the proportion of death or intensive care unit admission (risk ratio of 1.06 (95% CI 0.63-1.79)) or proportion of discharge or National Early Warning Score 2 (NEWS2) ≤ 2 within 14 days from enrollment (RR of 0.85 (95% CI 0.70-1.04)). Lactoferrin showed an excellent safety and tolerability profile. Even though bovine lactoferrin is safe and tolerable, our results do not support its use in hospitalized patients with moderate-to-severe COVID-19.
乳铁蛋白作为一种具有明确抗病毒和免疫调节能力的营养补充剂，可用于改善 COVID-19 的临床病程。在 LAC 随机双盲安慰剂对照试验中评估了牛乳铁蛋白的临床疗效和安全性。共有 218 名住院的中度至重度 COVID-19 成年患者随机分为接受 800 毫克/天口服牛乳铁蛋白（n = 113）或安慰剂（n = 105）组，两组均联合标准 COVID-19 治疗。乳铁蛋白与安慰剂在主要结局方面没有差异：死亡或入住重症监护病房的比例（风险比为 1.06（95%CI 0.63-1.79））或入组后 14 天内出院或国家早期预警评分 2（NEWS2）≤2 的比例（RR 为 0.85（95%CI 0.70-1.04））。乳铁蛋白表现出极佳的安全性和耐受性。尽管牛乳铁蛋白安全且耐受良好，但我们的结果不支持其在中重度 COVID-19 住院患者中的使用。
